Nevada enacted a law in 2023 legalizing certain non-FDA-approved biological and gene therapies for patients who meet specified criteria, placing it among the early states, alongside Florida and Utah, to build a state framework around therapies the FDA has not approved. The specifics of what that law requires of providers are not cleanly documented in accessible primary sources. Only what can be confirmed is stated below; the rest must be read from the Nevada Revised Statutes and confirmed with qualified Nevada counsel.
TLDR: Nevada enacted a 2023 law legalizing certain non-FDA-approved biological and gene therapies under defined conditions. The exact provider requirements, disclosure and consent obligations, and penalty structure should be verified directly against the Nevada Revised Statutes and with Nevada counsel, because they are not reliably documented in accessible secondary sources. Nevada’s 2025 legislative session produced no confirmed new stem cell provider disclosure law. Regardless of state law, the federal floor still applies: tissue must qualify as a 361 HCT/P or be used under an active IND. Treat Nevada as a jurisdiction needing active legal monitoring. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Nevada’s 2023 Law on Unapproved Biological and Gene Therapies
In 2023, Nevada enacted legislation legalizing certain non-FDA-approved biological and gene therapies for patients meeting specific criteria. This made Nevada one of the early movers in a trend of states creating their own frameworks for therapies the FDA has not approved, in parallel with Utah’s placental stem cell law and Florida’s authorization statute.
What the law permits in detail, the precise eligibility criteria for patients, the disclosure and consent obligations it imposes on providers, and the penalty structure for non-compliance, are not reliably documented in the accessible secondary record. A physician relying on this law must read the operative Nevada Revised Statutes text directly and confirm its scope with Nevada healthcare counsel. Commentators reviewing the law have noted that it does not clearly require the patient to have a terminal illness and may contain gaps around how the biologics must be manufactured, which is precisely the kind of ambiguity that makes independent legal review non-optional here.
What Nevada’s 2025 Legislative Session Did and Did Not Change
Nevada’s 2025 legislative session concluded in early June 2025. Based on the research available, no new stem cell provider disclosure law was confirmed as having passed during that session. Physicians should not assume the 2023 framework is the final word: verify the current status of any Nevada regulation with the Nevada Legislature and the Nevada State Board of Medical Examiners, and confirm with counsel whether any rulemaking has been issued to implement the 2023 law. The regulatory landscape in this area is moving quickly enough that any point-in-time summary should be re-verified before reliance.
The Federal Floor Still Applies in Nevada
This is the part that does not depend on Nevada at all. Whatever a state statute permits, it does not preempt federal law, and the FDA’s authority over unapproved biologics is unaffected by state legislation. A product that does not qualify as a 361 HCT/P under 21 CFR Part 1271 is regulated as a 351 biologic and must be used under an active investigational new drug application. The FDA has repeatedly warned that no stem cell product is approved for the broad range of conditions some clinics market, and it has taken enforcement action against Nevada-adjacent and nationwide operators alike. A Nevada physician who reads the 2023 law as a shield against federal enforcement has misread the relationship between state and federal authority. What separates a 361 tissue from a 351 product turns on minimal manipulation and homologous use, a distinction worth understanding in its own right.
How Nevada Compares to Other States
The comparison below places Nevada alongside the states with clearer frameworks. Cells marked as unverified reflect the genuine state of the accessible record for Nevada, not a drafting shortcut.
| State | Type of law | Effective | Key provider requirement | Penalty | Notes |
|---|---|---|---|---|---|
| Nevada (2023 law) | Authorization-style, scope unconfirmed | 2023 | Disclosure and consent, specifics unverified | Unverified, confirm with counsel | Verify all cells against Nevada Revised Statutes |
| Florida (SB 1768) | Authorization | July 1, 2025 | Accredited sourcing, signed consent, ad notice | Board of Medicine discipline | Orthopedics, wound care, pain only |
| Utah (58-1-512 / SB 275) | Disclosure plus supply chain | 2024, amended 2025 | Posted notice, signed consent, supplier notice | Unprofessional conduct / DOPL | Supplier obligation added 2025 |
| Wyoming (SF 48) | Authorization | July 1, 2026 | IRB or investigational status, cGMP, registration, consent | Board action limited if compliant | Autologous MSCs only |
| California (SB 512) | Disclosure-only | 2018 | Posted notice plus signed handout | Up to $1,000, not on first complaint | No authorization granted |
The Florida, Utah, Wyoming, and California frameworks are discussed in the companion overview of why physicians add adipose banking and the federal backdrop in FDA regulations for adipose tissue.
Risk Assessment for Nevada Providers
The practical recommendation is to treat Nevada as a jurisdiction that requires active legal monitoring rather than a one-time clearance. Before offering any non-FDA-approved stem cell therapy in Nevada, even under the 2023 law, conduct a state-specific legal review covering what the 2023 law actually authorizes, what disclosure and consent obligations apply, whether the Nevada State Board of Medical Examiners has issued implementing rules, and whether any 2025 or later amendments altered the picture. Layer the federal analysis on top: confirm the tissue’s regulatory classification independently of anything the state law says. The combination of unsettled state detail and unchanged federal authority is exactly the situation where proceeding on assumption is most expensive.
Frequently Asked Questions
Does Nevada’s 2023 law let a provider offer any unapproved biological therapy?
The law legalizes certain non-FDA-approved biological and gene therapies under specific conditions, but the precise scope and conditions should be read from the Nevada Revised Statutes and confirmed with counsel. The specific eligibility and provider criteria are not stated here because they could not be verified from a primary source.
Did Nevada pass a new stem cell disclosure law in 2025?
Based on available research, no new stem cell provider disclosure law was confirmed as passed in the 2025 session. Verify the current status with the Nevada Legislature and the Nevada State Board of Medical Examiners.
Does the 2023 law protect a Nevada provider from FDA enforcement?
No. State law does not preempt federal authority. Tissue must qualify as a 361 HCT/P or be used under an active IND regardless of what Nevada law permits.
Key Takeaways
Nevada belongs on the map of states that have legislated around unapproved biologics, but it is the hardest of the group to write about responsibly, because the accessible record does not pin down what the 2023 law requires of providers. The honest answer is that the operative requirements, the eligibility criteria, the disclosure and consent obligations, the penalties, must be read from the Nevada Revised Statutes and confirmed with Nevada counsel before a provider relies on any of them. The 2025 session does not appear to have added a new disclosure law, but that too should be re-verified. What is not in doubt is the federal floor: Nevada’s statute does not touch the FDA’s authority, so the 361-versus-351 classification of any tissue governs independently of state law. For a provider, the takeaway is procedural rather than substantive: treat Nevada as a monitor-and-verify jurisdiction, and remember that banking adipose tissue is a preservation decision separate from any therapy, with no guarantee of future use.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Nevada physicians weighing how tissue preservation fits a compliant practice can contact Save My Fat to discuss the operational side. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
